Sanofi India Receives GST Show Cause Notice for ₹23.74 Crore Demand
Sanofi India Limited received a GST Show Cause Notice for an alleged excess Input Tax Credit claim for FY 2022-23. The notice proposes a demand of ₹14.43 crore tax and ₹9.31 crore interest, totaling ₹23.74 crore. The company is examining the notice and expects no adverse financial impact.
The potential financial implication of ₹23.74 crore is material, although the company has stated no adverse impact is expected. This could lead to operational or legal follow-ups, warranting a medium impact assessment.
The announcement is a routine disclosure of a Show Cause Notice received from GST authorities. While a demand has been proposed, the company is in the process of responding and does not foresee any adverse financial impact, making the sentiment neutral.
Sanofi India Limited has received a Show Cause Notice dated 25th September 2026, issued under Section 73 of the Karnataka Goods and Services Tax Act, 2017. The notice, from the Commercial Tax Officer (Audit) -6.1, DGSTO -6, Bengaluru, alleges that the company has availed excess Input Tax Credit (ITC) for the period April 2022 to March 2023.
The GST authorities have proposed a tax liability of ₹14,43,01,828 along with interest of ₹9,30,74,679, aggregating to a total demand of ₹23,73,76,507.
The company is currently in the process of responding to the notice after gathering the relevant facts. Sanofi India, in consultation with its tax advisors, is examining the notice and will take appropriate steps, including submitting a reply within the prescribed timeframe. The company does not anticipate any adverse impact on its financials, operations, or other activities arising from this notice.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.